Condition
Neuroblastoma Recurrent clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Neuroblastoma Recurrent clinical trials that are recruiting, at sites in 9 countries (most in United States (2), Spain (2), Hong Kong (1)). By phase: Phase 2 (3), Phase 1 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 9Countries
Newest Neuroblastoma Recurrent clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Adding N-803 to chemoimmunotherapy for relapsed or refractory neuroblastoma | Phase 2 | San Francisco, California and 4 other locations | Recruiting | Jul 25, 2025 |
| Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma | Phase 1 | Boston, Massachusetts and 1 other locations | Recruiting | Jun 18, 2025 |
| Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents | Phase 1/2 | Boadilla del Monte, Madrid | Recruiting | Sep 23, 2024 |
| Quadruple immunotherapy for treating relapsed neuroblastoma in children | Phase 2 | Hong Kong | Recruiting | Mar 6, 2023 |
| 177Lu-DOTATATE treatment for children with high-risk neuroblastoma | Phase 2 | Copenhagen, Copenhagen and 8 other locations | Recruiting | May 27, 2021 |
All recruiting trials (5)
-
Adding N-803 to chemoimmunotherapy for relapsed or refractory neuroblastoma
This study tests whether adding the immune stimulant N-803 to a chemoimmunotherapy regimen helps children and young adults with relapsed or refractory neuroblastoma.
-
Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma
This trial will test whether giving the immunotherapy Naxitamab more slowly, along with irinotecan, temozolomide, and sargramostim, reduces infusion side effects for people with relapsed or refractory neuroblastoma.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
-
Quadruple immunotherapy for treating relapsed neuroblastoma in children
This study is testing a new combination of treatments to see if it can help children with relapsed neuroblastoma feel better and fight their cancer more effectively.
-
177Lu-DOTATATE treatment for children with high-risk neuroblastoma
This study is testing a new treatment called 177Lu-DOTATATE to see if it can help children with high-risk neuroblastoma that has come back or worsened.
Related topics
Quick answers
How many Neuroblastoma Recurrent clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 9 countries. The most sites are in United States (2 trials), Spain (2 trials), Hong Kong (1 trial), Denmark (1 trial), Lithuania (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.